XML 42 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value of Financial Instruments
12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Fair Value Measurements
Our available-for-sale securities, derivative instruments and certain non-marketable and other equity securities are financial instruments recorded at fair value on a recurring basis. We make estimates regarding valuation of assets and liabilities measured at fair value in preparing our consolidated financial statements. We disclose our method and approach for fair value measurements of assets and liabilities in Note 2—“Summary of Significant Accounting Policies” of the “Notes to the Consolidated Financial Statements” under Part II, Item 8 of this report.
The following fair value hierarchy table presents information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2018:
(Dollars in thousands)
 

Level 1
 

Level 2
 

Level 3
 
Balance at December 31, 2018
Assets
 
 
 
 
 
 
 
 
Available-for-sale securities:
 
 
 
 
 
 
 
 
U.S. Treasury securities
 
$
4,738,258

 
$

 
$

 
$
4,738,258

U.S. agency debentures
 

 
1,084,117

 

 
1,084,117

Foreign government debt securities
 
5,812

 

 

 
5,812

Residential mortgage-backed securities:
 
 
 
 
 
 
 
 
Agency-issued collateralized mortgage obligations— fixed rate
 

 
1,880,218

 

 
1,880,218

Agency-issued collateralized mortgage obligations— variable rate
 

 
81,638

 

 
81,638

Total available-for-sale securities
 
4,744,070

 
3,045,973

 

 
7,790,043

Non-marketable and other equity securities (fair value accounting):
 
 
 
 
 
 
 
 
Non-marketable securities:
 
 
 
 
 
 
 
 
Venture capital and private equity fund investments measured at net asset value
 

 

 

 
318,352

Venture capital and private equity fund investments not measured at net asset value (1)
 

 

 
1,079

 
1,079

Other equity securities in public companies
 
1,181

 
19,217

 

 
20,398

Total non-marketable and other equity securities (fair value
   accounting)
 
1,181

 
19,217

 
1,079

 
339,829

Other assets:
 
 
 
 
 
 
 
 
Foreign exchange forward and option contracts
 

 
100,402

 

 
100,402

Equity warrant assets
 

 
4,039

 
145,199

 
149,238

Client interest rate derivatives
 

 
8,499

 

 
8,499

Total assets
 
$
4,745,251

 
$
3,178,130

 
$
146,278

 
$
8,388,011

Liabilities
 
 
 
 
 
 
 
 
Foreign exchange forward and option contracts
 
$

 
$
88,559

 
$

 
$
88,559

Client interest rate derivatives
 

 
9,491

 

 
9,491

Total liabilities
 
$

 
$
98,050

 
$

 
$
98,050

 
(1)
Included in Level 3 assets is $0.9 million attributable to noncontrolling interests calculated based on the ownership percentages of the noncontrolling interests.
The following fair value hierarchy table presents information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2017:
(Dollars in thousands)
 
Level 1
 
Level 2
 
Level 3
 
Balance at December 31, 2017
Assets
 
 
 
 
 
 
 
 
Available-for-sale securities:
 
 
 
 
 
 
 
 
U.S. Treasury securities
 
$
6,840,502

 
$

 
$

 
$
6,840,502

U.S. agency debentures
 

 
1,567,128

 

 
1,567,128

Residential mortgage-backed securities:
 
 
 
 
 
 
 

Agency-issued collateralized mortgage obligations— fixed rate
 

 
2,267,035

 

 
2,267,035

Agency-issued collateralized mortgage obligations— variable rate
 

 
373,730

 

 
373,730

Equity securities
 
158

 
72,111

 

 
72,269

Total available-for-sale securities
 
6,840,660

 
4,280,004

 

 
11,120,664

Non-marketable and other equity securities (fair value accounting):
 
 
 
 
 
 
 
 
Non-marketable securities:
 
 
 
 
 
 
 
 
Venture capital and private equity fund investments measured at net asset value
 

 

 

 
127,192

Venture capital and private equity fund investments not measured at net asset value (1)
 

 

 
919

 
919

Other equity securities in public companies (1)
 
310

 

 

 
310

Total non-marketable and other equity securities (fair value
   accounting)
 
310

 

 
919

 
128,421

Other assets:
 
 
 
 
 
 
 
 
Foreign exchange forward and option contracts
 

 
96,636

 

 
96,636

Equity warrant assets
 

 
2,432

 
121,331

 
123,763

Client interest rate derivatives
 

 
11,753

 

 
11,753

Total assets
 
$
6,840,970

 
$
4,390,825

 
$
122,250


$
11,481,237

Liabilities
 
 
 
 
 
 
 
 
Foreign exchange forward and option contracts
 
$

 
$
96,641

 
$

 
$
96,641

Client interest rate derivatives
 

 
11,940

 

 
11,940

Total liabilities
 
$

 
$
108,581

 
$

 
$
108,581

 
(1)
Included in Level 1 and Level 3 assets are $0.2 million and $0.8 million, respectively, attributable to noncontrolling interests calculated based on the ownership percentages of the noncontrolling interests.
The following table presents additional information about Level 3 assets measured at fair value on a recurring basis for 2018, 2017 and 2016, respectively:
(Dollars in thousands)
 
Beginning
Balance
 
Total Realized and Unrealized Gains (Losses), net Included in Income
 
Sales/Exits
 
Issuances  
 
Distributions and Other Settlements
 
Transfers Out of Level 3
 
Ending
Balance
Year ended December 31, 2018:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-marketable and other equity securities (fair value accounting):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Venture capital and private equity fund investments not measured at net asset value (1)
 
$
919

 
$
457

 
$

 
$

 
$
(297
)
 
$

 
$
1,079

Other assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Equity warrant assets (2)
 
121,331

 
87,982

 
(78,752
)
 
17,941

 

 
(3,303
)
 
145,199

Total assets
 
$
122,250


$
88,439


$
(78,752
)

$
17,941


$
(297
)

$
(3,303
)

$
146,278

Year ended December 31, 2017:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-marketable and other equity securities (fair value accounting):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Venture capital and private equity fund investments not measured at net asset value (1)
 
$
2,040

 
$
971

 
$
(2,092
)
 
$

 
$

 
$

 
$
919

Other assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Equity warrant assets (2)
 
128,813

 
54,263

 
(74,769
)
 
14,537

 

 
(1,513
)
 
121,331

Total assets
 
$
130,853


$
55,234


$
(76,861
)

$
14,537


$


$
(1,513
)

$
122,250

Year ended December 31, 2016:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-marketable and other equity securities (fair value accounting):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Venture capital and private equity fund investments not measured at net asset value (1)
 
$
2,040

 
$
(21
)
 
$
(4
)
 
$

 
$
25

 
$

 
$
2,040

Other assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Equity warrant assets (2)
 
135,168

 
38,091

 
(56,643
)
 
13,405

 

 
(1,208
)
 
128,813

Total assets
 
$
137,208

 
$
38,070

 
$
(56,647
)
 
$
13,405

 
$
25

 
$
(1,208
)
 
$
130,853

 

(1)
Realized and unrealized gains (losses) are recorded in the line item “Gains on investment securities, net,” a component of noninterest income.
(2)
Realized and unrealized gains (losses) are recorded in the line item “Gains on equity warrant assets, net,” a component of noninterest income.
The following table presents the amount of unrealized gains (losses) included in earnings (which is inclusive of noncontrolling interest) attributable to Level 3 assets still held at December 31, 2018 and 2017, respectively:
 
 
Year ended December 31,
(Dollars in thousands)
 
2018
 
2017
Non-marketable and other equity securities (fair value accounting):
 
 
 
 
Venture capital and private equity fund investments not measured at net asset value (1)
 
$
160

 
$
(444
)
Other assets:
 
 
 
 
Equity warrant assets (2)
 
37,564

 
11,174

Total unrealized gains, net
 
$
37,724

 
$
10,730

Unrealized gains (losses) attributable to noncontrolling interests (1)
 
$
143

 
$
(397
)
 

(1)
Unrealized gains are recorded on the line item “gains on investment securities, net,” a component of noninterest income.
(2)
Unrealized gains are recorded on the line item “gains on equity warrant assets, net,” a component of noninterest income.
The extent to which any unrealized gains or losses will become realized is subject to a variety of factors, including, among other things, the expiration of current sales restrictions to which these securities are subject, the actual sales of securities and the timing of such actual sales.
The following table presents quantitative information about the significant unobservable inputs used for certain of our Level 3 fair value measurements at December 31, 2018 and 2017. We have not included in this table our venture capital and private equity fund investments (fair value accounting) as we use net asset value per share (as obtained from the general partners of the investments) as a practical expedient to determine fair value.
(Dollars in thousands)
 
Fair Value
 
Valuation Technique
 
Significant Unobservable Inputs
 
Weighted Average
December 31, 2018:
 
 
 
 
 
 
 
 
Venture capital and private equity fund investments (fair value accounting)
 
$
1,079

 
Private company equity pricing
 
(1)
 
(1)
Equity warrant assets (public portfolio)
 
2,757

 
Black-Scholes option pricing model
 
Volatility
 
54.7
%
Risk-Free interest rate
2.6

Sales restrictions discount (2)
18.5

Equity warrant assets (private portfolio)
 
142,442

 
Black-Scholes option pricing model
 
Volatility
 
38.5

Risk-Free interest rate
2.5

Marketability discount (3)
17.7

Remaining life assumption (4)
45.0

December 31, 2017:
 
 
 
 
 
 
 
 
Venture capital and private equity fund investments (fair value accounting)
 
$
919

 
Private company equity pricing
 
(1)
 
(1)
Equity warrant assets (public portfolio)
 
1,936

 
Black-Scholes option pricing model
 
Volatility
 
47.9
%
Risk-Free interest rate
2.1

Sales restrictions discount (2)
15.5

Equity warrant assets (private portfolio)
 
119,395

 
Black-Scholes option pricing model
 
Volatility
 
36.7

Risk-Free interest rate
1.8

Marketability discount (3)
16.4

Remaining life assumption (4)
45.0

 
 
(1)
In determining the fair value of our venture capital and private equity fund investment portfolio (not measured at net asset value), we evaluate a variety of factors related to each underlying private portfolio company including, but not limited to, actual and forecasted results, cash position, recent or planned transactions and market comparable companies. Additionally, we have ongoing communication with the portfolio companies and venture capital fund managers, to determine whether there is a material change in fair value. We use company provided valuation reports, if available, to support our valuation assumptions. These factors are specific to each portfolio company and a weighted average or range of values of the unobservable inputs is not meaningful.
(2)
We adjust quoted market prices of public companies, which are subject to certain sales restrictions. Sales restriction discounts generally range from 10 percent to 20 percent depending on the duration of the sales restrictions which typically range from three to six months.
(3)
Our marketability discount is applied to all private company warrants to account for a general lack of liquidity due to the private nature of the associated underlying company. The quantitative measure used is based upon various option-pricing models. On a quarterly basis, a sensitivity analysis is performed on our marketability discount.
(4)
We adjust the contractual remaining term of private company warrants based on our estimate of the actual remaining life, which we determine by utilizing historical data on terminations and exercises. At December 31, 2018, the weighted average contractual remaining term was 6.1 years, compared to our estimated remaining life of 2.7 years. On a quarterly basis, a sensitivity analysis is performed on our remaining life assumption.
During 2018, 2017 and 2016, we did not have any transfers between Level 2 and Level 1 or transfers between Level 3 and Level 1. All other transfers from Level 3 to Level 2 during 2018, 2017 and 2016 were due to the transfer of equity warrant assets from our private portfolio to our public portfolio (see our Level 3 reconciliation above). All amounts reported as transfers represent the fair value as of the date of the change in circumstances that caused the transfer.
Financial Instruments not Carried at Fair Value
FASB guidance over financial instruments requires that we disclose estimated fair values for our financial instruments not carried at fair value. The following fair value hierarchy table presents the estimated fair values of our financial instruments that are not carried at fair value at December 31, 2018 and 2017:
 
 
 
 
Estimated Fair Value
(Dollars in thousands)
 
Carrying Amount
 
Total
 

Level 1
 

Level 2
 

Level 3
December 31, 2018:
 
 
 
 
 
 
 
 
 
 
Financial assets:
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
3,571,539

 
$
3,571,539

 
$
3,571,539

 
$

 
$

Held-to-maturity securities
 
15,487,442

 
15,188,236

 

 
15,188,236

 

Non-marketable securities not measured at net asset value
 
131,453

 
131,453

 

 

 
131,453

Non-marketable securities measured at net asset value
 
151,247

 
151,247

 

 

 

Net commercial loans
 
25,043,671

 
25,463,968

 

 

 
25,463,968

Net consumer loans
 
3,013,706

 
3,064,093

 

 

 
3,064,093

FHLB and Federal Reserve Bank stock
 
58,878

 
58,878

 

 

 
58,878

Financial liabilities:
 
 
 


 
 
 
 
 
 
Short-term borrowings
 
631,412

 
631,412

 

 
631,412

 

Non-maturity deposits (1)
 
49,278,174

 
49,278,174

 
49,278,174

 

 

Time deposits
 
50,726

 
50,337

 

 
50,337

 

3.50% Senior Notes
 
347,639

 
336,088

 

 
336,088

 

5.375% Senior Notes
 
348,826

 
361,281

 

 
361,281

 

Off-balance sheet financial assets:
 
 
 
 
 
 
 
 
 
 
Commitments to extend credit
 

 
22,930

 

 

 
22,930

December 31, 2017:
 
 
 
 
 
 
 
 
 
 
Financial assets:
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
2,923,075

 
$
2,923,075

 
$
2,923,075

 
$

 
$

Held-to-maturity securities
 
12,663,455

 
12,548,280

 

 
12,548,280

 

Non-marketable securities (cost and equity method accounting) not measured at net asset value
 
120,019

 
126,345

 

 

 
126,345

Non-marketable securities (cost and equity method accounting) measured at net asset value
 
228,399

 
331,496

 

 

 

Net commercial loans
 
20,238,247

 
20,520,623

 

 

 
20,520,623

Net consumer loans
 
2,613,045

 
2,593,538

 

 

 
2,593,538

FHLB and Federal Reserve Bank stock
 
60,020

 
60,020

 

 

 
60,020

Financial liabilities:
 
 
 
 
 
 
 
 
 
 
Short-term borrowings
 
1,033,730

 
1,033,730

 
1,033,730

 

 

Non-maturity deposits (1)
 
44,206,929

 
44,206,929

 
44,206,929

 

 

Time deposits
 
47,146

 
46,885

 

 
46,885

 

3.50% Senior Notes
 
347,303

 
352,058

 

 
352,058

 

5.375% Senior Notes
 
348,189

 
374,483

 

 
374,483

 

Off-balance sheet financial assets:
 
 
 
 
 
 
 
 
 
 
Commitments to extend credit
 

 
22,208

 

 

 
22,208

 
(1)
Includes noninterest-bearing demand deposits, interest-bearing checking accounts, money market accounts and interest-bearing sweep deposits.
Investments in Entities that Calculate Net Asset Value Per Share
FASB guidance over certain fund investments requires that we disclose the fair value of funds, significant investment strategies of the investees, redemption features of the investees, restrictions on the ability to sell investments, estimate of the period of time over which the underlying assets are expected to be liquidated by the investee, and unfunded commitments related to the investments.
Our investments in debt funds and venture capital and private equity fund investments generally cannot be redeemed. Alternatively, we expect distributions, if any, to be received primarily through IPOs and M&A activity of the underlying assets of the fund. Subject to applicable requirements under the Volcker Rule, we do not have any plans to sell any of these fund investments. If we decide to sell these investments in the future, the investee fund’s management must approve of the buyer before the sale of the investments can be completed. The fair values of the fund investments have been estimated using the net asset value per share of the investments, adjusted for any differences between our measurement date and the date of the fund investment’s net asset value by using the most recently available financial information from the investee general partner, for example September 30th, for our December 31st consolidated financial statements, adjusted for any contributions paid, distributions received from the investment, and significant fund transactions or market events during the reporting period.
The following table is a summary of the estimated fair values of these investments and remaining unfunded commitments for each major category of these investments as of December 31, 2018:
(Dollars in thousands)
 
Carrying Amount      
 
Fair Value        
 
Unfunded Commitments      
Non-marketable securities (fair value accounting):
 
 
 
 
 
 
Venture capital and private equity fund investments (1)
 
$
318,352

 
$
318,352

 
$
12,973

Non-marketable securities (equity method accounting):
 
 
 
 
 
 
Venture capital and private equity fund investments (2)
 
129,485

 
129,485

 
4,943

Debt funds (2)
 
5,826

 
5,826

 

Other investments (2)
 
15,936

 
15,936

 
886

Total
 
$
469,599

 
$
469,599

 
$
18,802

 
(1)
Venture capital and private equity fund investments within non-marketable securities (fair value accounting) include investments made by our managed funds of funds and one of our direct venture funds (consolidated VIEs) and investments in venture capital and private equity fund investments (unconsolidated VIEs). Collectively, these investments in venture capital and private equity funds are primarily in U.S. and global technology and life science/healthcare companies. Included in the fair value and unfunded commitments of fund investments under fair value accounting are $87.1 million and $4.4 million, respectively, attributable to noncontrolling interests. It is estimated that we will receive distributions from the fund investments over the next 10 to 13 years, depending on the age of the funds and any potential extensions of terms of the funds.
(2)
Venture capital and private equity fund investments, debt funds, and other fund investments within non-marketable securities (equity method accounting) include funds that invest in or lend money to primarily U.S. and global technology and life science/healthcare companies. It is estimated that we will receive distributions from the funds over the next 5 to 8 years, depending on the age of the funds and any potential extensions of the terms of the funds.